◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksC › CURN

Curatis Holding AG (CURN) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

Curatis Holding AG (CURN) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Liestal, Switzerland with about 9 employees. Its market capitalization is roughly CHF 95 million. In the fiscal year ended 2025-12-31, CURN reported CHF 11M in revenue and (CHF 1M) in net income.

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.

Interactive charts & full statements →

CURN Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCHF 11MCHF 7MCHF 0MCHF 0M
Gross ProfitCHF 3MCHF 2MCHF 0M
Operating Income (EBIT)(CHF 2M)(CHF 3M)(CHF 4M)(CHF 2M)
Net Income(CHF 1M)(CHF 4M)(CHF 49M)(CHF 35M)

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CURN Free Cash Flow History

CURN Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCHF 56MCHF 56MCHF 0MCHF 14M
Total LiabilitiesCHF 10MCHF 10MCHF 0MCHF 7M

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CURN viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← CURIAll “C” companiesCURR →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.